Oruka Therapeutics, Inc. (ORKA) Revenue, Earnings & Financial Statements
$95.74NASDAQ: ORKAMarket Cap $6.49B
Data as of Nov 18, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Oruka Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $105.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Oruka Therapeutics, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $105.0M.
Income Statement — 11 Years (USD millions)
Metric
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
—
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
—
$17.0M
$19.0M
$8.0M
$6.0M
$10.0M
$19.0M
$10.0M
$7.0M
$88.0M
$122.0M
Operating Profit
—
−$17.0M
−$19.0M
−$8.0M
−$6.0M
−$10.0M
−$19.0M
−$10.0M
−$7.0M
−$88.0M
−$122.0M
Other Income
—
$0
$0
$0
$0
$0
$0
$0
$2.0M
$4.0M
$17.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$1.0M
$0
Depreciation
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
—
−$16.0M
−$19.0M
−$8.0M
−$6.0M
−$10.0M
−$19.0M
−$10.0M
−$5.0M
−$84.0M
−$105.0M
Tax rate (%)
—
0.0%
0.3%
0.4%
3.0%
0.1%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
—
−$16.0M
−$18.0M
−$8.0M
−$5.0M
−$10.0M
−$19.0M
−$10.0M
−$5.0M
−$84.0M
−$105.0M
EPS
$—
−$390.96
−$382.87
−$123.73
−$49.79
−$8.40
−$16.68
−$8.27
−$4.44
−$4.99
−$2.31
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$2.0M
$2.0M
$21.0M
$29.0M
$38.0M
$25.0M
$28.0M
$34.0M
$34.0M
$36.0M
$50.0M
$62.0M
Operating Profit
−$2.0M
−$2.0M
−$21.0M
−$29.0M
−$38.0M
−$25.0M
−$28.0M
−$34.0M
−$34.0M
−$36.0M
−$50.0M
−$62.0M
Interest
$0
$0
$0
$1.0M
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$1.0M
−$2.0M
−$22.0M
−$29.0M
−$33.0M
−$21.0M
−$25.0M
−$30.0M
−$30.0M
−$32.0M
−$41.0M
−$50.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$1.0M
−$2.0M
−$22.0M
−$29.0M
−$33.0M
−$21.0M
−$25.0M
−$30.0M
−$30.0M
−$32.0M
−$41.0M
−$50.0M
EPS
−$0.90
−$0.24
−$1.30
−$1.91
−$1.54
−$0.50
−$0.58
−$0.69
−$0.54
−$0.58
−$0.66
−$0.63
Over the 11 years reported for Oruka Therapeutics, Inc., cash stood at $47.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 22.93 times.
Balance Sheet — 11 Years (USD millions)
Metric
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
—
$25.0M
$12.0M
$7.0M
$9.0M
$50.0M
$55.0M
$43.0M
$38.0M
$396.0M
$489.0M
Current Assets
—
$21.0M
$12.0M
$7.0M
$8.0M
$50.0M
$54.0M
$43.0M
$38.0M
$377.0M
$344.0M
Cash
—
$7.0M
$9.0M
$7.0M
$8.0M
$49.0M
$53.0M
$42.0M
$37.0M
$62.0M
$47.0M
Inventory
—
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
—
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
—
$0
$0
$0
$0
$0
$0
$0
$0
$1.0M
$2.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$16.0M
$3.0M
$0
$0
$0
$0
$0
$0
$332.0M
$433.0M
Other Assets
—
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
—
$2.0M
$2.0M
$1.0M
$1.0M
$4.0M
$4.0M
$1.0M
$1.0M
$14.0M
$17.0M
Current Liabilities
—
$2.0M
$2.0M
$1.0M
$1.0M
$3.0M
$3.0M
$1.0M
$1.0M
$13.0M
$15.0M
Borrowings
$0
$0
$0
$0
$0
$0
$0
$0
$0
$1.0M
$2.0M
Other Liabilities
—
$2.0M
$2.0M
$1.0M
$1.0M
$3.0M
$3.0M
$1.0M
$1.0M
$13.0M
$15.0M
Equity
—
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
—
$22.0M
$10.0M
$6.0M
$8.0M
$47.0M
$51.0M
$42.0M
$37.0M
$382.0M
$472.0M
For Oruka Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $88.0M; free cash flow was positive in 0 of 11 years.
Cash Flow Statement — 11 Years (USD millions)
Metric
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$11.0M
−$15.0M
−$17.0M
−$8.0M
−$5.0M
−$8.0M
−$19.0M
−$11.0M
—
−$58.0M
−$88.0M
Investing Cash Flow
$0
−$16.0M
$13.0M
$3.0M
$0
$0
$0
$0
—
−$330.0M
−$97.0M
Financing Cash Flow
$0
$0
$0
$0
$0
$0
$0
$0
—
$0
$0
Net Cash Flow
$23.0M
−$31.0M
$1.0M
−$2.0M
$2.0M
$41.0M
$4.0M
−$11.0M
—
$24.0M
−$15.0M
Free Cash Flow
−$11.0M
−$15.0M
−$17.0M
−$8.0M
−$5.0M
−$8.0M
−$19.0M
−$11.0M
$0
−$58.0M
−$88.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-1.82
EV / EBITDA
-40.81
FCF Yield
-1.70%
Quick Ratio
29.62
Interest Coverage
—
Return 1Y
241.20%
Return 3Y
724.55%
Return 5Y
551.72%
Oruka Therapeutics, Inc. (ORKA) financials — frequently asked questions
What is Oruka Therapeutics, Inc.'s annual revenue?
Oruka Therapeutics, Inc. (ORKA) reported annual revenue of $0 in its most recent fiscal year.
What is Oruka Therapeutics, Inc.'s net profit?
Oruka Therapeutics, Inc. (ORKA) reported a net loss of $105.0M in its most recent fiscal year.
What is ORKA EV/EBITDA?
Oruka Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -40.81. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks